I miss the Dovonex scalp lotion. Also just regular Dovonex cream. Has anyone tried getting a compounding pharmacy to make up any Dovonex without the steroids?

As in the title, I need to find a shampoo that is free of sulfates and other chemicals and irritants. Hopefully easy to find and reasonably priced. Also a nice conditioner as well.

What would you recommend?

Thanks

Hi everyone,
I'm new to the forum so am hoping that I don't mess this up.
I've had psoriasis since 14 yrs of age (plaque and guttate). I'm now 47 and over the years have been prescribed various lotions and potions, had light treatment twice and spent a small fortune of things claiming to treat psoriasis effectively. I've had periods of not too bad skin and really awful flare ups. Following treatment for breast cancer 2 yrs ago my skin is the worst it's ever been.
My dermatologist agreed to prescribe Acitretin about 2 months ago. I started taking 10mg daily and suffered some mild side effects however at the monthly review my feet had started to peel and crack so badly, the Acitretin was reduced to 10mg on alternate days.
I'm so frustrated as I know that I'm probably well below the therapeutic dose and it's going to take so long to start working. I'm trying to remain positive about this medication but all I'm experiencing now is burning sore skin that is flakier than ever.
I wondered if anyone else had this experience and how long and at what dose they started to see effects?
Really grateful for any advice. 

Hi all, please introduce me. I'm basri from Indonesia. I've diagnosted psoriasis for more than 10 years ago. I feel so sad for hearg that this illness can't healed. tank you for make this forum. I'm sorry for my bad english.
b'regards
a. basri

ok so im going to try and make this short as possible i finally got a job with health care but it takes a few weeks to kick in so i want to get the ball rolling right away on dealing with these scars. My psoriasis is practically gone thats been my battle the past few years but now i face a new battle in treating the scars it left behind. Its only on my arms i have white spots that lost pigment and i really hope its not perminent. Any help is welcomed is anybody else dealing with this? I would post a pic but dont know how i just hope there is a chance i coudl atleast get some pigment back.

Samumed show preclinical results from in vitro and in vivo studies regarding the use of its small molecule compound SM04755 as a potential topical treatment for psoriasis.

Quote:

---

Samumed presented at the 2016 American College of Rheumatology (ACR) Annual Meeting preclinical results from in vitro and in vivo studies regarding the use of its small molecule compound SM04755 as a potential topical treatment for psoriasis. SM04755 is one of two small molecule Wnt pathway modulators (together with SM04690 which is in clinical trials for osteoarthritis and degenerative disc disease) for which Samumed has presented clinical and/or preclinical data across five different rheumatic diseases.
Psoriasis is an autoimmune disease of the skin, characterized by inflammation and fibrosis, producing patches of red, itchy and scaly skin. (Dees C and Distler JH. Exp Dermatol. 2013;22(11):710-3.) From in vitro studies, SM04755 inhibited inflammation, keratinocyte proliferation, and fibrosis. In an in vivo mouse model, topically applied SM04755 inhibited inflammation, cell proliferation, and decreased skin thickness compared to vehicle. These studies demonstrated that SM04755 has potential as a topical therapy for psoriasis.
Samumed presented, inter alia, the following images related to its in vivo study as part of its presentation at ACR on this potential treatment for psoriasis.

“Based on our study results, we are excited about SM04755’s potential as a treatment for psoriasis. Treatment of mild to moderate psoriasis using a safe and effective topical agent remains an area of intense medical research,” said Yusuf Yazici, M.D., Chief Medical Officer of Samumed. “Our Phase 1 trial for chronic tendinopathy using the same topical investigational drug will form the basis to expand into a Phase 2 study for psoriasis in 2017.”
From in vitro studies, anti-inflammatory activity was evaluated by measuring IL-6 and TNF-α secretion using ELISA in Lipopolysaccharides-stimulated THP-1 monocytes and anti-CD3/anti-CD28-stimulated peripheral blood mononuclear cells. Cytokine-induced keratinocyte proliferation was measured in primary human keratinocytes using an EdU incorporation assay. Finally, the effect on fibrosis was assessed in TGF-β1-stimulated human dermal fibroblasts by measuring smooth muscle actin, plasminogen activator inhibitor, connective tissue growth factor, and collagen expression by qPCR.
In vivo efficacy was evaluated in an imiquimod (IMQ)-induced mouse psoriasis model with daily topical IMQ (0.3mg/cm2) application on the back and ear for 20 days, along with daily treatment with topical SM04755 starting on day 3 after the first IMQ application. Efficacy was assessed by measurement of skin and ear thickness, spleen size and weight, cytokine levels in plasma, and histological measurements of inflammation. Dermal and epidermal thickness were assessed by hematoxylin & eosin staining and proliferation in the skin using bromodeoxyuridine labeling.

Hello everyone

I have had psoriasis since I was 15 im now 31 .....tried most creams/ointments nothing much worked until my dermatologist put me on methotrexate...this was great but I had terrible side affects, I have heard lots of good things about stelara.
I think at my next dermatolgy appointment I will ask to go on this as Im currently having an awful flare up.
Jenna 

Here's another Bio going for FDA approval. Guselkumab targets the protein interleukin (IL)-23.

Quote:

---

Janssen Biotech, Inc. (Janssen) announced today the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of guselkumab for the treatment of adults living with moderate to severe plaque psoriasis. Guselkumab is a human monoclonal antibody that targets interleukin (IL)-23, a protein which has been shown to play a key role in the development of immune-mediated inflammatory diseases. Psoriasis is a chronic, autoimmune inflammatory disorder that results in the overproduction of skin cells, characterized by raised, inflamed, scaly, red lesions, or plaques, which can cause itching, discomfort and pain. It is estimated that 7.5 million Americans have psoriasis, which can range from mild to severe and disabling.

"We are committed to translating scientific advances into innovative therapies for chronic immune-mediated diseases like plaque psoriasis," said Newman Yeilding, M.D., Head of Immunology Development, Janssen Research & Development, LLC. "We look forward to working with the FDA during the agency's review of the application as we believe guselkumab addresses continued needs of patients living with moderate to severe plaque psoriasis."

Data from four studies evaluating the efficacy and safety of guselkumab administered by subcutaneous injection in the treatment of adults living with moderate to severe plaque psoriasis served as the basis for the submission. These studies include VOYAGE 1, VOYAGE 2 and NAVIGATE Phase 3 studies, and the X-PLORE Phase 2 study, which appeared in The New England Journal of Medicine in July 2015. Results from the VOYAGE 1 study were recently presented at the European Academy of Dermatology and Venereology congress, and results from the VOYAGE 2 and NAVIGATE studies are planned for presentation at upcoming scientific congresses.

One for the DMF Gang. Ask them on Psoriasis Club, we have a few of them willing to give a personal experience.

Quote:

---

Background:
Fumaric acid esters (FAEs) are recommended in international guidelines for induction and long-term treatment of adults with moderate-to-severe chronic plaque psoriasis. The fixed combination Fumaderm® is approved in Germany, with dimethyl fumarate (DMF) being the main active ingredient.

Objectives:
To assess the efficacy and safety of a new formulation of DMF (LAS41008), compared with placebo and Fumaderm®, in adults with moderate-to-severe chronic plaque psoriasis.

Methods:
In this phase III, double-blind, placebo-controlled, noninferiority trial (BRIDGE, NCT01726933, EudraCT 2012-000055-13), patients were randomized to receive LAS41008, Fumaderm® or placebo (2 : 2 : 1) for 16 weeks, uptitrating to a maximum daily DMF dose of 720 mg, depending upon individual response. The coprimary end points were the percentage of patients achieving ≥ 75% improvement in Psoriasis Area and Severity Index (PASI 75) and the percentage achieving a score of ‘clear’ or ‘almost clear’ in the Physician's Global Assessment (PGA) at week 16.

Results:
In total, 671 patients were randomized and included in the full analysis set (n = 267, LAS41008; n = 273, Fumaderm®; n = 131, placebo). At week 16, 37·5% of patients treated with LAS41008 achieved PASI 75, compared with 15·3% receiving placebo (superiority for LAS41008 vs. placebo: P < 0·001) and 40·3% receiving Fumaderm® (noninferiority for LAS41008 vs. Fumaderm®: P < 0·001). Overall, 33% of patients treated with LAS41008 were ‘clear’ or ‘almost clear’ in the PGA at week 16, compared with 13·0% receiving placebo (P < 0·0001; LAS41008 superiority vs. placebo) and 37·4% receiving Fumaderm®. Most treatment-related adverse events were classed as ‘mild’ in severity.

Conclusions:
LAS41008 (DMF) is effective in the treatment of adults with moderate-to-severe chronic plaque psoriasis.

More good news for Cosentyx and it's use for psoriatic arthritis.

Quote:

---

Novartis announced today new data showing Cosentyx® (secukinumab) delivers sustained improvements in the signs and symptoms of psoriatic arthritis (PsA) over three years - including patient-reported pain. These findings were presented at the 2016 Annual Meeting of the American College of Rheumatology (ACR) in Washington DC, United States, at which Novartis presented 28 abstracts in total.

Cosentyx is the first approved fully human interleukin-17A (IL-17A) inhibitor to demonstrate   three-year efficacy in patients with PsA, a life-long inflammatory disease that affects the skin and joints. Cosentyx is also the only IL-17A inhibitor indicated for ankylosing spondylitis (AS), PsA, and psoriasis - this is significant as up to eight in 10 patients diagnosed with PsA already have psoriasis.

"Joint pain severely impacts the lives of many people living with psoriatic arthritis. The knowledge that Cosentyx delivers lasting pain relief, reduces swelling and helps keep joints moving is important as it means it could help improve both patient overall quality of life and mobility," said Vasant Narasimhan, Global Head, Drug Development and Chief Medical Officer, Novartis. "Cosentyx provides much-needed pain relief and also delivers high and long-lasting skin clearance for psoriasis, which the majority of people with psoriatic arthritis also suffer from."

In the first year of the three-year open-label extension study, which is a continuation of the two-year double-blind study previously reported, 77% of PsA patients achieved an ACR 20 response (American College of Rheumatology response criteria) with Cosentyx. Completion rates for the extension study were high with 95% patients completing the first year of the extension trial. These new data show that response rates were consistent from Year 1 (69.4%) to Year 3 (76.8%) and this was independent of whether patients received an anti-TNF prior to receiving Cosentyx. Importantly, a component of this measure includes patient-reported pain. Cosentyx has previously shown 79% of AS patients achieved an ASAS 20 response (Assessment of Spondyloarthritis International Society response criteria) at two years. Previous data also show up to 80% of AS and 84% of PsA patients treated with Cosentyx at two years had no radiographic progression in the spine or joints respectively, as shown by X-ray assessment. Cosentyx continues to have a favorable safety profile, which was consistent with that shown in Phase III studies.
                                             
In addition, analyses, using Matching-Adjusted Indirect Comparison (MAIC) presented at ACR show Cosentyx may improve the signs and symptoms of AS and PsA more than Humira® (adalimumab). In a new MAIC for AS, the ASAS 20 response rates at Week 52 were higher for Cosentyx (74%) than for Humira® (65%). Likewise, in the MAIC for PsA patients, ACR 20 response rates at Week 48 were higher for Cosentyx (72%) than for Humira® (56%).

Following these MAIC analyses, Novartis plans to initiate new head-to-head clinical trials to directly compare Cosentyx versus Humira® in patients with AS and PsA. These will include 850 patients and will be the first ever adequately powered head-to-head studies with biologic medicines to differentiate the effectiveness of treatment in these conditions.

This study evaluated the long term trends of biologic use outside the realm of clinical trials. The following Bio's were used.
Enbrel (etanercept)
Humira (adalimumab)
Remicade (infliximab)
Stelara (ustekinumab)

Quote:

---

Background/Objectives:
Data on biologic drug survival in real-world psoriasis treatment are limited. There is a need to evaluate long-term trends of biologic use outside the realm of clinical trials.

Methods:
A multicentre chart review was conducted with patients' data from September 2005 to September 2014. Kaplan–Meier plot analysis was used to determine 5-year drug survival rates. A log–rank test was used to compare the rates of drug survival between the studied biologics.

Results:
For the 398 patients and 545 treatment series analysed, 1, 2, 3, 4 and 5-year survival rates were 0.826, 0.687, 0.563, 0.475 and 0.420 with etanercept; 0.804, 0.648, 0.553, 0.508 and 0.508 with adalimumab; 0.838, 0.664, 0.554, 0.485 and 0.382 with infliximab; and 0.914, 0.856, 0.800, 0.755 and 0.755 with ustekinumab, respectively. A statistically significant difference was seen between ustekinumab and the other three biologics.

Conclusion:
A progressive decrease in treatment adherence was seen with all four biologics, as expected, but the survival rate of ustekinumab was highest.

This small study of 90 patients with psoriasis was conducted to assess the presence of entheseal abnormalities as detected by ultrasound, and to determine any correlation with nail involvement.

Quote:

---

Background:
Although subclinical enthesopathy is a well-established diagnostic criterion for psoriatic arthritis (PsA), it is frequently overlooked, as many patients are asymptomatic. The possibility of finding a clinical clue predicting enthesopathy would help clinicians establish an early diagnosis of PsA.

Material and methods:
A prospective single-center study of a total of 90 patients with psoriasis was conducted to assess the presence of entheseal abnormalities as detected by ultrasound, and to determine any correlation with nail involvement.

Results:
Entheseal abnormalities were found in 23 patients (25.5 %), 19 (82.6 %) of whom showed nail involvement, whereas four (17.4 %) individuals did not. Enthesopathy was present in 31.1 % (19/61) of patients with onychopathy compared to 13.8 % (4/29) of those without nail involvement (p = 0.07). There was a significant correlation between target NAPSI score and evidence of enthesopathy. In addition, the number of nails affected also showed a significant correlation with the presence of enthesopathy (p  = 0.035).

Conclusions:
Clinical evidence of onychopathy may be the clue to an early diagnosis of enthesopathy in psoriasis patients.

Hi I am Jen. I've had psoriasis since I was 10 years old (now 40). I've got guttate, plaque, inverse, scalp,PsA, and I had bout of Von Zumbusch.

Since it's been 30 years, I've been on a million different creams, ointments, etc. I'm currently only using topicals but I'm planning to return to biologics. I'm in the midst of a horrible flare.

Beyond psoriasis, I am a mom to two kids, a wife, a school paraprofessional to a girl with CP, and an avid reader.

Hey Everyone! 

Just made an account, was recently diagnosed with Palmoplantar Pustulosis Psoriasis. I've had this now for about 3 months, it only affects my hands and feet. 

My finger nails on one hand have the typical excess skin under the nail forcing the nail off etc and my hands are peeling, red, itchy but not really sore. 

My feet however are where the real problem is, I have several lacerations and new ones opening on a regular basis making it extremely difficult to walk and i'm in quite some pain no matter what i'm doing with my feet.

I'm only 23 and this just kind of came out of nowhere, i don't mind the aesthetics, I guess i'm lucky in that not many people see your feet but even the finger nails and hands it's not a big deal for me, the issue is with the effect it is having on my quality of life, I train MMA 5 days a week, I cycle a lot I walk places etc and I haven't been able to train for nearly 3 months now, it's getting me down not to mention the pain of just walking around in every day life.

Any advise or tips for dealing with this would be much appreciated, thanks!!

Hi, my name is Emir. I am 17 years old and bave been living with psoriasis since i was just 2, back in  2001. I got diagnosed cause od stress , a dog attack. I have  been able to cut my psoriasis down to just my elbows, knees and feet  However... For 3 Years i faintly belive my doctor that i have  foot fungus which is extremely painful. I was able to Pierce the skin and get all of the green pus run out. After it appears,it lasts a few days , turns brown and i Peel off all of my skin. It grows back and after about a month or less comes back. I am attatching photos so you Guys can  see ,comment and share your experiences, perhaps even diagnose or Help me. Thanks in  advance

I am a woman 58, just was diagnose of psoriasis... not 100%   , but very close, going to see dermatologist next week..
I am covered by terrible red spots (a lot!) - hands look ugly, legs too, but other parts of the body start to show these red spots... Feel very frustrated..How can i go to south vacation - i look scary for people.

Hello everyone

I find there is not much information about Acitretin when it comes to treating disorders other than psoriasis.
I have been suffering from seborrheic dermatitis and folliculitis on the scalp and chest for about 10 years, I am a 25 year old male.

My folliculitis is whats bothering me the most. I have been on Tetralysal before which did not help me and I just got prescribed Acitretin 10mg to take every day. 
I'm sorry if my question is not fit for this forum but does anyone here have any information or experience when it comes to treating these disorders with Acitretin?

Anyone taking Consentyx every experience at Hairloss, about to take the drug and wondering if this is one of the side effects.

I am about to start consentyx and I am a 37 year old male.  We are planning to have our second child and wondering if this affects a man in conceiving or the baby

I have very minor psoriasis (it is never thick, doesn't flake and I've never had a patch much bigger than a coin) and less than 1% of my body is covered  but recently I have noticed I am getting small pimples appear on my legs, mainly on the calves. If I didn't have psoriasis I wouldn't be at all concerned about them but because I do and have heard about pustular psoriasis I'm wondering if that is what it is. 

The only treatment I've had for psoriasis is topical creams, namely Dovonex and Dovobet.  I use Dovobet once on Saturdays and Sundays and Dovonex twice a day on week days. I know a side effect of topical steroids is folliculitis and I'm wondering if it's that? I have noticed there has been a hair coming directly through the middle of the pimple a few times but it's not always the case as you can see in the pics. I have to admit I sometimes lightly prick these pimples with a sterilised needle and gently squeeze them after which they disappear after a few days. I've never had more than two at any one time but a new one will pop up every few days or so.. 

Here is a couple of pics of two different pimples on the back of each leg.